The latest from NuvOx

Tucson, AZ  – November 24, 2025  – Today NuvOx Therapeutics, Inc. (“NuvOx”) along with Dr. Pavani Chalasani of George Washington University announced the acceptance of abstracts in Triple Negative Breast Cancer (TNBC) at 2 prestigious conventions, titled “Novel Oxygen Therapeutic Shows Promise in Boosting Immunotherapy Response in Triple Negative Breast Cancer”. Researchers at George Washington (GW) University Cancer Center, in collaboration with NuvOx, have demonstrated that

Tucson, Arizona — November 12, 2025 — NuvOx Therapeutics, Inc. (“NuvOx”), a clinical-stage biotechnology company developing oxygen therapeutics to enhance the efficacy of cancer treatment, today announced the progress from the ongoing RESTORE Phase IIb clinical trial of NanO₂™ in patients with newly diagnosed glioblastoma (GBM) will be presented at the 2025 Society for Neuro-Oncology (SNO) Annual Meeting in Honolulu, HI. The presentation will be in a poster session by the Cen

Tucson, Arizona — November 6, 2025 — NuvOx Therapeutics (“NuvOx”), a clinical-stage biotechnology company developing oxygen therapeutics to treat life-threatening hypoxemic conditions, announced encouraging initial safety and oxygenation data from the first cohort of the ongoing EXTEND-1b Phase Ib clinical trial of NanO₂™ (dodecafluoropentane emulsion) in patients with mild respiratory distress. Such results will be presented as a scientific poster at the Critical Care Canada

Tucson, AZ  – September 26, 2025 – NuvOx Therapeutics, Inc. (“NuvOx”) and FYR Bio (“FYR”) today announced a collaboration pairing NuvOx’s...

Tucson, AZ  – September 26, 2025 - NuvOx Therapeutics, Inc. (“NuvOx”) announced that it has appointed Mr. Wilson W. Cheung, CPA, as an...